Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Veralox Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Veralox Expands Pipeline with Exclusive Option to Acquire Nudge Therapeutics
Details : Through the acquisition, Veralox expands its pipeline by including preclinical cyclic AMP-GMP (cGAS) inhibitor compounds.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Veralox Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?